Publications by authors named "S A Harrow"
Background And Objectives: Faricimab, a bispecific antibody targeting VEGF-A and angiopoietin-2, has shown promise in treating neovascular age-related macular degeneration (nAMD). This study evaluates 1-year outcomes of faricimab in treatment-experienced nAMD patients.
Methods: This single-centre retrospective cohort study included patients previously treated for nAMD who switched to faricimab between November 2022 and March 2024.
Article Synopsis
- - The SABR-SYNC trial aims to evaluate the effectiveness of stereotactic ablative radiotherapy (SABR) in patients with oligometastatic cancers that have a synchronous primary tumor, addressing a gap in phase III data currently available.
- - One hundred and eighty patients will be randomly assigned to receive either standard care treatment or standard care plus SABR, with various dosing and treatment modalities used depending on the physician's clinical judgement.
- - The trial will focus on overall survival as the main goal, while also examining factors like progression-free survival, quality of life, and potential biomarkers from circulating tumor DNA to improve future treatment decisions.
Purpose: Radiation pneumonitis (RP) is a dose-limiting toxicity for patients undergoing radiotherapy (RT) for lung cancer, however, the optimal practice for diagnosis, management, and follow-up for RP remains unclear. We thus sought to establish expert consensus recommendations through a Delphi Consensus study.
Methods: In Round 1, open questions were distributed to 31 expert clinicians treating thoracic malignancies.
Background: Stereotactic Ablative Radiotherapy (SABR) for the treatment of oligometastatic disease can improve survival and delay the requirement for systemic therapy. The benefits of SABR in oligoprogressive disease are less well-defined. Here, we evaluate the available evidence investigating the efficacy of SABR in the treatment of oligoprogressive disease.
View Article and Find Full Text PDFArticle Synopsis
- * Conducted across six institutions in Canada and Scotland, the research enrolled patients aged 18 and older with specific eligibility criteria and administered SABR with a total dose of 50 Gy in five sessions.
- * Results showed a promising 1-year overall survival rate of 79%, indicating that SABR could be a beneficial treatment despite the patients' high risk of treatment-related toxic effects.